Cerebrospinal fluid levels of chromogranin A in the treatment-na < ve early stage Parkinson's disease: a pilot study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F13%3A%230000502" target="_blank" >RIV/00098892:_____/13:#0000502 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/13:33145086

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Cerebrospinal fluid levels of chromogranin A in the treatment-na < ve early stage Parkinson's disease: a pilot study

Popis výsledku v původním jazyce

Chromogranin A (CgA) levels in cerebrospinal fluid (CSF) have been reported to be significantly reduced in the later stages of Parkinson's disease (PD). There are only limited data regarding its levels in the early stages, so its significance as a potential biomarker in the diagnosis of PD cannot be established. The aim of our study was to establish the level of CgA in a cohort of treatment-na < ve patients with early stage PD. Ten patients (4 males, 6 females) and 10 gender- and age-matched controls were examined for CgA levels in the CSF. Control subjects were patients with low-back pain or tension-type headache. The mean CSF CgA level in PD patients was 74.8 (41.9-123.8) mu g/l; in the control group it was 143.9 (116-181.3) mu g/l. Statistical analysis showed a difference at the significance level P a parts per thousand currency sign 0.05. Our pilot study shows that CSF CgA levels are reduced in the early stages of PD. CgA could therefore be a potential biomarker helpful in the diag

Název v anglickém jazyce

Cerebrospinal fluid levels of chromogranin A in the treatment-na < ve early stage Parkinson's disease: a pilot study

Popis výsledku anglicky

Chromogranin A (CgA) levels in cerebrospinal fluid (CSF) have been reported to be significantly reduced in the later stages of Parkinson's disease (PD). There are only limited data regarding its levels in the early stages, so its significance as a potential biomarker in the diagnosis of PD cannot be established. The aim of our study was to establish the level of CgA in a cohort of treatment-na < ve patients with early stage PD. Ten patients (4 males, 6 females) and 10 gender- and age-matched controls were examined for CgA levels in the CSF. Control subjects were patients with low-back pain or tension-type headache. The mean CSF CgA level in PD patients was 74.8 (41.9-123.8) mu g/l; in the control group it was 143.9 (116-181.3) mu g/l. Statistical analysis showed a difference at the significance level P a parts per thousand currency sign 0.05. Our pilot study shows that CSF CgA levels are reduced in the early stages of PD. CgA could therefore be a potential biomarker helpful in the diag

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12221" target="_blank" >NT12221: Markery neurodegenerace v diferenciální diagnostice parkinsonských syndromů</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neural Transmission

ISSN

0300-9564

e-ISSN

—

Svazek periodika

120

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

5

Strana od-do

1559-1563

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—